Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that Mr. Ronald Hao Xi Ede will retire from his position as the chief financial officer after a seven-year distinguished career with the Company. Mr. Ede will continue to serve on the Board as an executive director, participating in the Board’s strategic and business decisions, as well as serve as the managing partner of the Company’s funds and take full charge of the Company’s fund management.
Mr. Ede joined Innovent in 2017 and, during his CFO tenure, has made significant contributions to the Company’s strategy planning, corporate governance, financial management and business development. He successfully led the listing of the Company on the Main Board of the Hong Kong Stock Exchange and a series of post-listing fund raising activities, which have laid a solid foundation for Innovent’s continuous growth.
At the same time, Innovent has appointed Ms. Fei You as the new CFO, effective February 5, 2024. She will be responsible for Innovent’s financial management and capital market activities. Ms. You has over 20 years of experience in financial management, strategic investment and financing. Before joining Innovent, she served as the chief financial officer of Jinxin Fertility Group Ltd. (HKEx stock code: 1951) and successfully led its listing on the Main Board of the Hong Kong Stock Exchange. Prior to that, she had served in various managerial positions with 3SBio Inc. (HKEx stock code: 1530) and KPMG.
“We are deeply grateful for the dedication and contribution Ronnie has made during his entire tenure at Innovent. His strategic judgment and leadership were instrumental in transforming Innovent from a biotech company to a biopharma enterprise, and leaves us in a solid position to continue pursuing our long-term global vision. We will continue to work with him on the Board of the Company and in other areas, “said Dr. Michael Yu, Founder, Chairman and CEO of Innovent Biologics. “At the same time, we warmly welcome Ms. Fei You as our new CFO. Ms. You has extensive expertise and experience in financial management and capital markets in the healthcare industry. We look forward to working with her on the journey toward pursuing our mission of ‘developing high-quality biopharmaceuticals that are affordable to ordinary people’ and our vision of “being one of the world’s leading biopharmaceutical companies.'”
SOURCE : PRNewswire